[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2011008843A - Anticuerpos humanizados que se unen a cd19 y sus usos. - Google Patents

Anticuerpos humanizados que se unen a cd19 y sus usos.

Info

Publication number
MX2011008843A
MX2011008843A MX2011008843A MX2011008843A MX2011008843A MX 2011008843 A MX2011008843 A MX 2011008843A MX 2011008843 A MX2011008843 A MX 2011008843A MX 2011008843 A MX2011008843 A MX 2011008843A MX 2011008843 A MX2011008843 A MX 2011008843A
Authority
MX
Mexico
Prior art keywords
seq
amino acid
acid sequence
bind
humanized antibodies
Prior art date
Application number
MX2011008843A
Other languages
English (en)
Inventor
Stanislas Blein
Martin Bertschinger
Darko Skegro
Christophe Debonneville
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MX2011008843A publication Critical patent/MX2011008843A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061Blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72Increased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a anticuerpos humanizados o fragmentos de los mismos que se unen al CD19 humano; más específicamente, la presente invención se refiere a un anticuerpo humanizado o fragmento del mismo que se une al CD19 humano, que comprende una CDR1 de cadena pesada que comprende la secuencia de aminoácidos del SEQ ID NO: 27, y/o una CDR2 de cadena pesada que comprende la secuencia de aminoácidos del SEQ ID NO: 28, y/o una CDR3 de cadena pesada que comprende la secuencia de aminoácidos del SEQ ID NO: 29; y/o que comprende una CDRI de cadena ligera que comprende la secuencia de aminoácidos del SEQ ID NO: 30, y/o una CDR2 de cadena ligera que comprende la secuencia de aminoácidos del SEQ ID NO: 31, y/o una CDR3 de cadena ligera que comprende la secuencia de aminoácidos del SEQ ID NO: 32.
MX2011008843A 2009-02-23 2010-02-23 Anticuerpos humanizados que se unen a cd19 y sus usos. MX2011008843A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15452409P 2009-02-23 2009-02-23
PCT/IB2010/000353 WO2010095031A2 (en) 2009-02-23 2010-02-23 Humanized antibodies that bind to cd19 and their uses

Publications (1)

Publication Number Publication Date
MX2011008843A true MX2011008843A (es) 2011-12-14

Family

ID=42115917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008843A MX2011008843A (es) 2009-02-23 2010-02-23 Anticuerpos humanizados que se unen a cd19 y sus usos.

Country Status (17)

Country Link
US (2) US8679492B2 (es)
EP (1) EP2398829A2 (es)
JP (1) JP2012518404A (es)
KR (1) KR20110122859A (es)
CN (1) CN102421800A (es)
AP (1) AP2011005859A0 (es)
AU (1) AU2010215239A1 (es)
BR (1) BRPI1005984A2 (es)
CA (1) CA2753158A1 (es)
CL (1) CL2011002039A1 (es)
CO (1) CO6430469A2 (es)
EA (1) EA201190132A1 (es)
IL (1) IL214725A0 (es)
MX (1) MX2011008843A (es)
SG (1) SG173654A1 (es)
WO (1) WO2010095031A2 (es)
ZA (1) ZA201106369B (es)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2539370B1 (en) * 2010-02-23 2019-05-15 Sanofi Anti-alpha2 integrin antibodies and their uses
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
KR20220101745A (ko) * 2010-12-09 2022-07-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
WO2012096975A2 (en) * 2011-01-13 2012-07-19 The Board Of Trustees Of The Leland Stanford Junior University Method of predicting responsiveness of b cell lineage malignancies to active immunotherapy
CN108285488B (zh) 2011-03-25 2023-01-24 伊克诺斯科学公司 异二聚体免疫球蛋白
DK2731677T3 (en) 2011-07-11 2018-06-18 Glenmark Pharmaceuticals Sa ANTIBODIES. BINDING TO OX40 AND THEIR USES
ES2909720T3 (es) 2011-08-16 2022-05-10 Morphosys Ag Terapia de combinación con un anticuerpo anti-CD19 y un análogo de purina
HUE058350T2 (hu) 2011-08-16 2022-07-28 Morphosys Ag Kombinációs terápia, CD19 elleni ellenanyag és nitrogénmustár alkalmazásával
KR20150076172A (ko) 2012-09-25 2015-07-06 그렌마크 파머수티칼스 에스. 아. 이질-이합체 면역글로불린의 정제
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
MX364329B (es) * 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
PE20151289A1 (es) 2013-01-02 2015-10-05 Glenmark Pharmaceuticals Sa Anticuerpos que se unen al tl1a y sus usos
EP2970372B1 (en) 2013-03-15 2020-09-30 Celgene Corporation Modified t lymphocytes
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2014210209A2 (en) * 2013-06-27 2014-12-31 Abbvie Biotherapeutics Inc. Fc variants with improved complement activation
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
JP6685900B2 (ja) * 2013-10-31 2020-04-22 フレッド ハッチンソン キャンサー リサーチ センター 改変された造血幹/前駆細胞及び非エフェクターt細胞、そしてそれらの用途
US9493563B2 (en) 2013-11-04 2016-11-15 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
JP6779785B2 (ja) 2013-12-19 2020-11-04 ノバルティス アーゲー ヒトメソテリンキメラ抗原受容体およびその使用
KR102487608B1 (ko) 2014-04-07 2023-01-12 노파르티스 아게 항-cd19 키메라 항원 수용체를 사용한 암의 치료
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016061368A1 (en) * 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
MA41480A (fr) 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
JP7068820B2 (ja) 2014-12-03 2022-05-17 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法のための方法および組成物
US11248058B2 (en) * 2015-02-19 2022-02-15 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
SI3280729T1 (sl) 2015-04-08 2022-09-30 Novartis Ag Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
US20180100026A1 (en) * 2015-04-15 2018-04-12 California Institute For Biomedical Research Optimized chimeric receptor t cell switches and uses thereof
EP3995142A3 (en) * 2015-04-29 2022-08-24 Fred Hutchinson Cancer Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
FI3298033T4 (fi) 2015-05-18 2023-09-22 Tcr2 Therapeutics Inc Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille
EP3603672A1 (en) 2015-05-26 2020-02-05 MorphoSys AG Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
WO2017015783A1 (en) * 2015-07-24 2017-02-02 Shanghai Sidansai Biotechnology Co., Ltd Humanized anti-cd19 antibody and use thereof
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
EP3337506B1 (en) 2015-08-21 2021-07-21 MorphoSys AG Combinations and uses thereof
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
AR106188A1 (es) * 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055314A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
MA43378A (fr) * 2015-12-03 2018-10-10 Juno Therapeutics Inc Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PT3916392T (pt) 2016-05-30 2024-06-04 Incyte Corp Métodos para prever o benefício terapêutico da terapia anti-cd19 nos pacientes
IL263764B2 (en) 2016-06-27 2024-09-01 Morphosys Ag Anti-CD19 antibody formulations
AU2017341047B2 (en) 2016-10-07 2024-10-10 Novartis Ag Chimeric antigen receptors for the treatment of cancer
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3528851B1 (en) 2016-10-20 2022-04-27 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
IL301786A (en) 2016-10-28 2023-05-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and uses thereof
EP3544996A2 (en) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN116120454A (zh) * 2017-01-05 2023-05-16 上海煦顼技术有限公司 人源化抗cd19抗体及其与嵌合抗原受体的用途
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
ES2871001T3 (es) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
CN106967171B (zh) * 2017-02-23 2021-04-27 郑州大学 一种全人源重组CD40L单抗Fab片段及其制备方法
JP2020517609A (ja) 2017-04-18 2020-06-18 メディミューン リミテッド ピロロベンゾジアゼピン複合体
AU2018256436A1 (en) 2017-04-19 2019-11-07 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
JOP20180042A1 (ar) * 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
EP3621640A4 (en) 2017-05-10 2021-06-30 The Wistar Institute Of Anatomy And Biology OPTIMIZED NUCLEIC ACID ANTIBODIES CONSTRUCTIONS
BR112019025034A2 (pt) 2017-05-31 2020-06-30 Morphosys Ag combinação
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
JP7279011B2 (ja) 2017-07-10 2023-05-22 インターナショナル-ドラッグ-ディベロップメント-バイオテック 抗cd20抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗cd19抗体を用いるb細胞悪性の治療
US11447546B2 (en) * 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
RS62928B1 (sr) 2017-08-18 2022-03-31 Medimmune Ltd Konjugati pirolobenzodiazepina
TWI812645B (zh) 2017-09-21 2023-08-21 中國大陸商上海藥明生物技術有限公司 新型抗cd19抗體
WO2019089478A1 (en) 2017-10-30 2019-05-09 Neuropore Therapies, Inc. Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
WO2019112347A2 (ko) * 2017-12-06 2019-06-13 앱클론(주) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
CN109053899B (zh) * 2017-12-22 2021-11-16 湖南远泰生物技术有限公司 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体
US11708409B2 (en) 2017-12-22 2023-07-25 Abclon Inc. Antibody or antigen-binding fragment thereof that specifically recognizes B cell malignancies, chimeric antigen receptor comprising same, and uses thereof
CN108047332B (zh) * 2018-01-15 2021-08-24 阿思科力(苏州)生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR20210020932A (ko) 2018-06-13 2021-02-24 노파르티스 아게 Bcma 키메라 항원 수용체 및 이의 용도
CN109293774B (zh) * 2018-10-16 2021-05-28 南京医科大学 特异性结合cd19的全人源化抗体及应用
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11793834B2 (en) 2018-12-12 2023-10-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
JP7090780B2 (ja) * 2018-12-21 2022-06-24 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Cd3に結合する抗体
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
US20220177579A1 (en) * 2019-04-08 2022-06-09 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
MA55797A (fr) * 2019-04-30 2022-03-09 Crispr Therapeutics Ag Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19
KR20220007087A (ko) 2019-05-03 2022-01-18 모르포시스 아게 제한된 수의 nk 세포를 갖는 환자에서의 항-cd19 치료제
BR112021026382A2 (pt) * 2019-06-27 2022-02-08 Crispr Therapeutics Ag Uso de células t de receptor de antígenos quimérico e inibidores de células nk para tratamento de câncer
CN110396129B (zh) * 2019-07-10 2020-11-24 武汉思安医疗技术有限公司 人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用
JP2022550435A (ja) 2019-10-04 2022-12-01 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 組換えaavの改善された治療的使用のための方法
WO2021084063A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
MX2022005031A (es) 2019-10-31 2022-07-27 Morphosys Ag Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas.
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CR20220637A (es) 2020-06-19 2023-01-31 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
TW202216193A (zh) 2020-06-22 2022-05-01 德商莫菲西斯公司 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法
WO2022076573A1 (en) 2020-10-06 2022-04-14 Xencor, Inc. Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
WO2022105811A1 (zh) * 2020-11-20 2022-05-27 江苏先声药业有限公司 Cd19人源化抗体及其应用
TW202237184A (zh) 2020-12-04 2022-10-01 德商莫菲西斯公司 抗cd19組合療法
WO2022155375A2 (en) * 2021-01-13 2022-07-21 Washington University MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME
CN112679612B (zh) * 2021-01-29 2022-07-01 武汉华美生物工程有限公司 抗cd19人源化抗体及其制备方法与应用
US20240270842A1 (en) * 2021-05-07 2024-08-15 Viela Bio, Inc Use of an anti-cd19 antibody to treat myasthenia gravis
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators
WO2024222859A1 (zh) * 2023-04-28 2024-10-31 深圳深信生物科技有限公司 经修饰的递送载体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
AU4116793A (en) * 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
JP5312721B2 (ja) * 2000-11-07 2013-10-09 シティ・オブ・ホープ Cd19特異的再指向免疫細胞
US20030194406A1 (en) * 2001-05-31 2003-10-16 Chiron Corporation P-cadherin as a target for anti-cancer therapy
US20030157108A1 (en) * 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
KR20110140143A (ko) * 2002-11-26 2011-12-30 애보트 바이오테라퓨틱스 코포레이션 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체
WO2005012493A2 (en) * 2003-07-31 2005-02-10 Immunomedics, Inc. Anti-cd19 antibodies
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
EP1853718B1 (en) * 2005-02-15 2015-08-05 Duke University Anti-cd19 antibodies and uses in oncology
EP2221316A1 (en) * 2005-05-05 2010-08-25 Duke University Anti-CD19 antibody therapy for autoimmune disease
CA2611814A1 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico

Also Published As

Publication number Publication date
WO2010095031A2 (en) 2010-08-26
US8679492B2 (en) 2014-03-25
CA2753158A1 (en) 2010-08-26
ZA201106369B (en) 2012-05-30
CN102421800A (zh) 2012-04-18
AU2010215239A1 (en) 2011-09-15
AP2011005859A0 (en) 2011-10-31
CO6430469A2 (es) 2012-04-30
US20100215651A1 (en) 2010-08-26
EA201190132A1 (ru) 2013-01-30
SG173654A1 (en) 2011-09-29
JP2012518404A (ja) 2012-08-16
IL214725A0 (en) 2011-11-30
KR20110122859A (ko) 2011-11-11
US20140286934A1 (en) 2014-09-25
WO2010095031A3 (en) 2010-11-04
CL2011002039A1 (es) 2012-03-30
EP2398829A2 (en) 2011-12-28
BRPI1005984A2 (pt) 2016-10-04

Similar Documents

Publication Publication Date Title
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ712765A (en) Antibodies that bind csf1r
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
NZ599683A (en) Anti-ilt7 antibody
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
NZ608660A (en) Anti-cd48 antibodies and uses thereof
NZ603226A (en) Anti-c5a antibodies and methods for using the antibodies
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
HRP20171472T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora puta tkivnog faktora (tfpi)
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
NZ594682A (en) Fully human antibodies specific to cadm1
NZ597611A (en) Anti notch-1 antibodies
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
AR078796A1 (es) Composiciones y metodos para tratar trastornos inflamatorios
NZ781203A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal